Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis
Open Access
- 24 February 2024
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (6) , 765-776
Abstract
Steroid-refractory graft-versus-host disease (SR-GvHD) represents a major complication of pediatric allogenic hematopoietic stem cell transplantation. Ruxolitinib, a selective JAK 1–2 inhibitor, showed promising results in the treatment of SR-GvHD in adult trial, including patients >12 years old. This systematic review aims to evaluate ruxolitinib use for SR-GvHD in the pediatric population. Among the 12 studies included, ruxolitinib administration presented slight differences. Overall response rate (ORR) ranged from 45% to 100% in both acute and chronic GvHD. Complete response rates (CR) varied from 9% to 67% and from 0% to 28% in aGvHD and cGvHD, respectively. Individual-patient meta-analysis from 108 children under 12 years showed an ORR and CR for aGvHD of 74% and 56%, respectively, while in cGvHD ORR was 78% but with only 11% achieving CR. Treatment-related toxicities were observed in 20% of patients, including cytopenia, liver toxicity, and infections. Age, weight, graft source, previous lines of therapy, and dose did not significantly predict response, while a higher rate of toxicities was observed in aGvHD patients. In conclusion, ruxolitinib shows promising results in the treatment of SR-GvHD in children, including those under 12 years. Specific pediatric perspective trials are currently ongoing to definitely assess its efficacy and safety.Keywords
This publication has 67 references indexed in Scilit:
- Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinibLeukemia, 2013
- Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practiceBone Marrow Transplantation, 2013
- Treatment and management of graft-versus-host disease: improving response and survivalTherapeutic Advances in Hematology, 2013
- First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2012
- Diagnosis and management of acute graft‐versus‐host diseaseBritish Journal of Haematology, 2012
- Steroid-Refractory Acute GVHD: Predictors and OutcomesAdvances in Hematology, 2011
- Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint StatementTransplantation and Cellular Therapy, 2009
- Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II studyThe Lancet, 2008
- Infliximab for GVHD therapy in childrenBone Marrow Transplantation, 2007
- Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantationAmerican Journal of Hematology, 2006